COPD-PH: statins improve SPAP and 6-minute walk distance

  • Wang G & al.
  • Eur J Intern Med
  • 31 Oct 2019

  • International Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Statins improve systolic pulmonary artery pressure (SPAP) and 6-minute walk distance (6MWD) in patients with COPD plus pulmonary hypertension (COPD+PH) as a comorbidity, according to a small meta-analysis.

Why this matters

  • 5-year survival rate was only 36% in patients with COPD with a mean pulmonary artery pressure (mPAP) of >25 mm Hg vs 62% in patients with an mPAP of

Study design

  • Meta-analysis of 5 randomised controlled trails (RCTs; n=270) after a search of MEDLINE, Cochrane, ISI Web of Science, and Scopus.
  • Funding: None disclosed.

Key results

  • Statins reduced SPAP (weighted mean difference [WMD], −4.52 [95% CI, −6.32 to −2.72] mm Hg; I2=0%) relative to placebo.
  • Statins (vs placebo) increased 6MWD (WMD, 32.46 [95% CI, 13.63-51.29] m; I2=73%).
  • Statins (vs placebo) did not improve forced expiratory volume in 1 second (WMD, 2.58%; 95% CI, −4.89% to 10.05%; I2=0%).

Limitations

  • Small number of studies, participants.
  • No data on statin doses.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit